M
Mark M. Davis
Researcher at Stanford University
Publications - 623
Citations - 84251
Mark M. Davis is an academic researcher from Stanford University. The author has contributed to research in topics: T cell & T-cell receptor. The author has an hindex of 144, co-authored 581 publications receiving 74358 citations. Previous affiliations of Mark M. Davis include Washington University in St. Louis & University of Chicago.
Papers
More filters
Transformation ofT-Lymphoid Cells byAbelson Murine Leukemia Virus
Mark M. Davis,Mark B. Feinberg +1 more
TL;DR: The consistent T-lymphoid phenotype exhibited by primary A-MuLVthymomas mayrepresent onestage of normal thymocyte differentiation, and beendefined hereby flowcytometry of 10primary tumors samples stained withantibodies toseveral thymocytes differentiation antigens.
Journal ArticleDOI
Mass Cytometry Defines Virus-Specific CD4+ T Cells in Influenza Vaccination.
Priyanka B. Subrahmanyam,Tyson H. Holmes,Dongxia Lin,Laura F. Su,Gerlinde Obermoser,Jacques Banchereau,Virginia Pascual,Adolfo García-Sastre,Randy A. Albrecht,Karolina Palucka,Mark M. Davis,Holden T. Maecker +11 more
TL;DR: An approach for identifying novel influenza virus–reactive CD4+ T cell subsets, a method that could help advance understanding of the immune response to influenza, predict responsiveness to vaccines, and aid in better vaccine design is presented.
Journal ArticleDOI
In Praise of Descriptive Science: A Breath of Fresh AIRE
TL;DR: It is found that subjects lacking the AIRE gene, critical for self-tolerance in T lymphocytes, show a broad range of autoantibody specificities, which can have extremely high affinities.
Journal ArticleDOI
Erratum: Apoptosis and other immune biomarkers predict influenza vaccine responsiveness (Molecular Systems Biology (2013) 9 (659) DOI: 10.1038/msb.2013.15)
David Furman,Vladimir Jojic,Brian A. Kidd,Shai S. Shen-Orr,Jordan V. Price,Justin A. Jarrell,Tiffany Tse,Huang Huang,Peder Lund,Holden T. Maecker,Paul J. Utz,Cornelia L. Dekker,Daphne Koller,Mark M. Davis +13 more
Journal Article
The long-term safety of pegylated recombinant methionyl human soluble tumor necrosis factor type i (peg stnf-ri): an extension study for rheumatoid arthritis patients completing previous peg stnf-ri clinical studies.
Michael Schiff,Daniel E. Furst,Stanley N. Cohen,Roy Fleischmann,Michael Macri,Tenshang Joh,Thomas Liu,Mark M. Davis +7 more